NCT02461563View on ClinicalTrials.gov

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 23, 2015

Primary Completion Date

December 23, 2015

Study Completion Date

December 23, 2015

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

200 mg MK-1075

Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days

DRUG

400 mg MK-1075

Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days

DRUG

800 mg MK-1075

Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02461563 - A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004) | Biotech Hunter | Biotech Hunter